Compare BZAI & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BZAI | SABS |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | 254 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.7M | 201.4M |
| IPO Year | N/A | N/A |
| Metric | BZAI | SABS |
|---|---|---|
| Price | $2.42 | $3.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $4.67 | ★ $10.75 |
| AVG Volume (30 Days) | ★ 9.2M | 380.8K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $239.02 | N/A |
| Revenue Next Year | $45.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $1.60 |
| 52 Week High | $6.76 | $6.60 |
| Indicator | BZAI | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 62.43 | 47.35 |
| Support Level | $2.12 | $3.55 |
| Resistance Level | $2.45 | $4.11 |
| Average True Range (ATR) | 0.27 | 0.24 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 65.97 | 38.81 |
Blaize Holdings Inc provides transformative artificial intelligence (AI)-enabled edge computing solutions comprised of both its proprietary hardware and software, and third-party hardware solutions. Its portfolio includes programmable AI processors in various form factors, which can be deployed across sectors such as smart cities, defense, retail, and enterprise markets. The company operates as a single operating and reportable segment. The majority of the company's revenue is derived from Hardware revenue, which includes the sale of its semiconductor products and/or third-party hardware products that support semiconductor products through various supply agreements. Geographically, it generates the maximum revenue from China.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.